b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29877701</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>04</Month>\n            <Day>03</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>04</Month>\n            <Day>03</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1520-4995</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>57</Volume>\n                    <Issue>28</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>07</Month>\n                        <Day>17</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Biochemistry</Title>\n                <ISOAbbreviation>Biochemistry</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>\xce\xb1-Helix or \xce\xb2-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>4148-4154</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.biochem.8b00105</ELocationID>\n            <Abstract>\n                <AbstractText>Peptide agonists acting on the glucagon-like peptide 1 receptor (GLP-1R) promote glucose-dependent insulin release and therefore represent important therapeutic agents for type 2 diabetes (T2D). Previous data indicated that an N-terminal type II \xce\xb2-turn motif might be an important feature for agonists acting on the GLP-1R. In contrast, recent publications reporting the structure of the full-length GLP-1R have shown the N-terminus of receptor-bound agonists in an \xce\xb1-helical conformation. To reconcile these conflicting results, we prepared N-terminally constrained analogues of glucagon-like peptide 1 (GLP-1) and exendin-4 and evaluated their receptor affinity and functionality in vitro; we then examined their crystal structures in complex with the extracellular domain of the GLP-1R and used molecular modeling and molecular dynamics simulations for further investigations. We report that the peptides\' N-termini in all determined crystal structures adopted a type II \xce\xb2-turn conformation, but in vitro potency varied several thousand-fold across the series. Potency correlated better with \xce\xb1-helicity in our computational model, although we have found that the energy barrier between the two mentioned conformations is low in our most potent analogues and the flexibility of the N-terminus is highlighted by the dynamics simulations.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Oddo</LastName>\n                    <ForeName>Alberto</ForeName>\n                    <Initials>A</Initials>\n                    <Identifier Source="ORCID">0000-0002-5759-9988</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Global Research , Novo Nordisk A/S , Novo Nordisk Park , 2760 M\xc3\xa5l\xc3\xb8v , Denmark.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mortensen</LastName>\n                    <ForeName>Sofia</ForeName>\n                    <Initials>S</Initials>\n                    <Identifier Source="ORCID">0000-0003-1631-6651</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Global Research , Novo Nordisk A/S , Novo Nordisk Park , 2760 M\xc3\xa5l\xc3\xb8v , Denmark.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Th\xc3\xb8gersen</LastName>\n                    <ForeName>Henning</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Global Research , Novo Nordisk A/S , Novo Nordisk Park , 2760 M\xc3\xa5l\xc3\xb8v , Denmark.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>De Maria</LastName>\n                    <ForeName>Leonardo</ForeName>\n                    <Initials>L</Initials>\n                    <Identifier Source="ORCID">0000-0002-8061-4242</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Global Research , Novo Nordisk A/S , Novo Nordisk Park , 2760 M\xc3\xa5l\xc3\xb8v , Denmark.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hennen</LastName>\n                    <ForeName>Stephanie</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Global Research , Novo Nordisk A/S , Novo Nordisk Park , 2760 M\xc3\xa5l\xc3\xb8v , Denmark.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>McGuire</LastName>\n                    <ForeName>James N</ForeName>\n                    <Initials>JN</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Global Research , Novo Nordisk A/S , Novo Nordisk Park , 2760 M\xc3\xa5l\xc3\xb8v , Denmark.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kofoed</LastName>\n                    <ForeName>Jacob</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Global Research , Novo Nordisk A/S , Novo Nordisk Park , 2760 M\xc3\xa5l\xc3\xb8v , Denmark.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Linderoth</LastName>\n                    <ForeName>Lars</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Global Research , Novo Nordisk A/S , Novo Nordisk Park , 2760 M\xc3\xa5l\xc3\xb8v , Denmark.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Reedtz-Runge</LastName>\n                    <ForeName>Steffen</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Global Research , Novo Nordisk A/S , Novo Nordisk Park , 2760 M\xc3\xa5l\xc3\xb8v , Denmark.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>06</Month>\n                <Day>21</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Biochemistry</MedlineTA>\n            <NlmUniqueID>0370623</NlmUniqueID>\n            <ISSNLinking>0006-2960</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000067757">Glucagon-Like Peptide-1 Receptor</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>89750-14-1</RegistryNumber>\n                <NameOfSubstance UI="D052216">Glucagon-Like Peptide 1</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>9P1872D4OL</RegistryNumber>\n                <NameOfSubstance UI="D000077270">Exenatide</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000077270" MajorTopicYN="N">Exenatide</DescriptorName>\n                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>\n                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D052216" MajorTopicYN="N">Glucagon-Like Peptide 1</DescriptorName>\n                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>\n                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000067757" MajorTopicYN="N">Glucagon-Like Peptide-1 Receptor</DescriptorName>\n                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000072756" MajorTopicYN="N">Protein Conformation, alpha-Helical</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000072757" MajorTopicYN="N">Protein Conformation, beta-Strand</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>6</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>4</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>6</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29877701</ArticleId>\n            <ArticleId IdType="doi">10.1021/acs.biochem.8b00105</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'